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ABSTRACT
Background. Brain imaging in stroke diagnostics is a powerful tool, but one that can fail in more challenging cases, and one 
that is not particularly useful in identifying transient ischaemic attacks (TIAs). Thus, new reliable blood biomarkers of cerebral 
ischaemia are constantly sought. 
Objective. We studied the potential usefulness of sphingolipids (SFs) as biomarkers of acute ischaemic stroke and TIA. 
Material and methods. Levels of individual ceramide species and sphingosine-1-phosphate (Sph-1-P) in blood serum of pa-
tients with acute ischaemic stroke, TIA, and age-matched neurological patients without cerebral ischaemia, were assessed by 
tandem mass spectrometry liquid chromatography (LC- MS / MS). 
Results. We found significant increases of several sphingolipid levels, with particularly strong elevations of Cer-C20:0 in patients 
with acute stroke. Cer-C24:1 was the only ceramide species to decrease as a result of acute stroke. Moreover, its levels inversely 
correlated with the number of days after stroke onset, suggesting that Cer-C24:1 is an independent parameter related to the 
course of stroke. To increase the sensitivity of sphingolipid-based tests in stroke diagnostics, we calculated the values of ratios of 
Sph-1-P / individual ceramide species and Cer-C24:1 individual ceramide species. We found several ratios significantly changed 
in stroke patients. Two ratios, Sph-1-P / Cer-C24:1 and Cer-C24:0 / Cer-C24:1, presented especially strong increments in patients 
with acute stroke. Moreover, Sph-1-P / Cer-C24:1 values were augmented in TIA patients. 
Conclusion. Serum SFs could be good candidates to be ischaemic stroke biomarkers. We have identified two SF ratios, Sph-1-P 
/ Cer-C24:1 and Cer-C24:0 / Cer-C24:1, with strong diagnostic potential in ischaemic stroke. We found Sph-1-P / Cer-C24:1 ratio 
to be possibly useful in TIA diagnostics, also in the long term after ischaemic incidence.
Key words: ischaemic stroke marker, biomarker, brain, ceramide, mass spectrometry, observational clinical studies, sphingoli-
pid, sphingosine-1-phosphate (Sph-1-P), transient ischaemic attack (TIA)
(Neurol Neurochir Pol 2019; 53 (6): 484–491)
Introduction
A diagnosis of ischaemic stroke is entirely based on neurolo-
gical outcomes and brain imaging [1]. Although neuroima-
ging is a powerful technique for identifying brain ischaemia, 
it has many limitations. Using computer tomography (CT), 
the identification of an early ischaemic incident (i.e. less 
than three hours from onset) can be challenging and frequ-
ently requires the use of brain contrast agents [1]. In more 
difficult cases, only by the employment of a combination 
of several neuroimaging techniques can a full picture of the 
patient’s condition be obtained. This is however not always 
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feasible in a hospital setting. Moreover, the conditions of 
many patients substantially hinder the use of magnetic 
resonance imaging (MRI), which enables the recognition of 
early ischaemic stroke. 
Another important issue is the diagnosis of TIA, which is ma-
inly identified based on the ischaemic stroke-like symptoms, 
and is often challenging to confirm using CT / MR scans. Blood 
biomarkers will certainly not replace imaging studies in stroke 
diagnostics, but they do give several advantages in relation to 
CT / MR scans. Firstly, they can be helpful in the identification 
of early acute ischaemic stroke and TIA. The extended brain 
image-based diagnostics often require the patient being trans-
ported to a more specialist institution, which is not necessary 
when blood markers are analysed. The ideal stroke biomarker 
would allow physicians to follow the stroke course, showing 
the time of reperfusion, and helping to predict the outcome.
The thromboembolic occlusion of the brain vessel leads to 
compromising of the blood-brain barrier (BBB), and enables 
blood elements to pass into brain parenchyma [2], as well as 
the leakage of inflammatory mediators and components of 
the damaged neuronal cells into the circulation. Many brain-
-derived and coagulation-related factors have been analysed 
to find the most useful ischaemic stroke biomarkers [3]. These 
factors have included IL-6, TNFα, GFAP, S100β, D-dimers 
or thrombin-anti-thrombin complex, and several others. 
Although promising initial results were obtained, their clinical 
accuracy was insufficient. 
In our study, we proposed ceramide (Cer) and sphingosi-
ne-1-phosphate (Sph-1-P) as potential ischaemic stroke 
biomarkers, the biological features of which could allow 
several stroke-related processes to be tracked in the future. 
Cer is composed of sphingoid base, at large d18:1, linked to 
fatty acid chain. Acyl chain in Cer varies greatly in length 
and bond saturation [4, 5]. The most common pathways of 
Cer generation are de novo synthesis and sphingomyelin 
hydrolysis. Over-activations of both pathways have been 
reported in animal models of cerebral ischaemia [6–8]. The 
Cer form diversity is created by several Cer synthases [9]. 
Little is known about the specific functions of individual 
Cer species since they have been predominantly studied in 
regards to cell membrane structure [10]. In contrast to Cer, 
Sph-1-P exerts biological functions by binding to its recep-
tors, although alternative pathways have also been reported 
[11]. Cerebral ischaemia alters both Cer and Sph-1-P con-
centrations in affected tissues. Cer accumulates in the brain 
shortly after ischaemia and has generally been considered to 
be a mediator of neurodegeneration [12–14]. Cer created in 
the brain can potentially get through the impaired BBB to the 
circulation, changing Cer profiles in blood serum / plasma. 
In contrast to Cer, the amounts of Sph-1-P tend to decrease 
in ischaemic stroke [15]. Sph-1-P reaches particularly high 
concentrations in blood, where it is mainly produced by 
red blood cells and endothelial cells [16]. However, during 
clot formation, Sph-1-P stored in high amounts in platelets 
is released extracellularly, and increases substantially the 
Sph-1-P content in blood serum [17]. It is known that Sph-1-
-P augments the level of plasminogen activator inhibitor-1 
(PAI-1) [18], and thus can constrain fibrinolysis. This may 
impede spontaneous recanalisation in stroke patients, and 
produce more severe brain insults.
Although there is a great deal of data on Cer and Sph-1-P 
changes in post-stroke animal brains, almost nothing is known 
about stroke-induced sphingolipid alterations in human blood. 
The main goal of this study was to establish whether Cer 
and Sph-1-P levels are altered in the serum of patients after 
ischaemic brain stroke and TIA, and whether they could in 
future be considered as potential ischaemic stroke biomarkers. 
Moreover, in calculating the ratios of selected SFs, we have 
attempted to find a method of SF data presentation which 
would make the obtained results more informative for their 
potential use in stroke diagnostics.
Material and methods
Baseline characteristics of the patients
The overall characteristics of the patients are set out in Table 1. 
103 patients were enrolled in the study. 42 were diagnosed with 
ischaemic stroke on the basis of specific symptoms and CT and 
MR scans. The grade of neurological dysfunction was assessed 
at admission using the NIH Stroke Scale (NIHSS). TIA was 






Acute cerebral  
ischaemia  
(n = 42)
Females (%) 60 63 67
Males (%) 40 37 33
Age – median (Q1; Q3) 69.5 (62; 78.5) 71 (62.5; 78.5) 76 (71.5; 82)
Patients with diabetes (%) 15 15 39
Patients with hypertriglyceridemia (%) 21 21 21
Patients with hypercholesterolemia (%) 24 27 18
Patients with renal disease (%) 15 15 36
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identified in 27 patients on the basis of ischaemic stroke-like 
symptoms that had disappeared within 24 hours of onset and 
did not exhibit changes in image scans. Among the 34 parti-
cipants in the control group were age-matched patients of the 
Neurological Department suffering from various neurological 
disorders but who had not experienced an ischaemic stroke 
/ TIA. These neurological diseases included sciatica, polyneu-
ropathy, spinal disc herniation, epilepsy, Parkinson’s disease, 
cervicobrachial syndrome, cerebrovascular disease, and facial 
nerve disorder. The common morphological and biochemical 
parameters were measured in all persons enrolled in the study. 
Patients were classified as those with hypercholesterolemia and 
hypertriglyceridemia by assessing the levels of total cholesterol 
and triglycerides in the blood, respectively. The cut off was 
established at 150 mg / dL for triglyceride level and 190 mg% 
for total cholesterol level. Subjects with diabetes were identified 
based on the medical history and a glucose tolerance test. Renal 
disease was diagnosed by assessing the levels and clearance of 
creatinine (above 1.17 mg / dL) as well as an estimated glome-
rular filtration rate (eGFR) of less than 60mL / min.
Blood samples were collected after receiving informed consent 
approved by the local ethics board (The Regional Medical 
Chamber in Krakow), according to the Declaration of Helsinki. 
Blood was drawn 2-21 days after ischaemic stroke onset, and 
2-7 days after TIA.
Lipid isolation
Lipids from blood serum were extracted on the basis of the 
method described by Folch et al. [19]. Before extraction, se-
rum samples were spiked with internal standards, d17:0-Cer 
or d17:1-Sph-1-P AVANTI (Polar Lipids Inc., Alabaster, AL, 
USA). 1 mL of a chloroform / methanol mixture (2:1, v / v) 
and 1 ml of 0.15M NaCl solutions were added to the serum 
sample. Then the mixture was shaken vigorously and placed 
into an ultrasonic bath for 10 min. Phases were separated by 
centrifugation (1,900 xg, 3 min), and the chloroform layer 
was evaporated in centrifugal vacuum concentrators at 60°C 
(Labconco, Kansas City, MO, USA). Dry residue was resuspen-
ded in 1,000 µl phase B (acetonitrile / 2-propanol (60:40, 
v / v) containing 0.2% formic acid) and filtered with a 0.22 
µm PTFE syringe filter.
Sphingolipid analysis
The assay was conducted using the technique of Kasumov et 
al. (2006) [20] with slight modifications. Pure standards of 
Cers (CerC14:0, CerC16:0, CerC18:0, CerC20:0, CerC24:0 
and CerC24:1) and Sph-1-P were obtained from AVANTI 
Polar Lipids. Extracted samples were injected into Agilent 
1200 HPLC and separated through a ZORBAX Eclipse Plus 
C18 column (2.1 × 50 mm, 3,5 μm, (Agilent Technologies, Palo 
Alto, CA, USA). The Cers were resolved using a gradient star-
ting from 50% mobile phase A (water containing 0.2% formic 
acid) at a flow rate of 0.3 mL / min for 1 min, to 100% mobile 
phase B [acetonitrile / 2-propanol (60:40, v / v) containing 
0.2% formic acid] over 3 min at a linear gradient, and then 
with 100% B for 12 min. The column was then equilibrated 
with 50% mobile phase B. The HPLC column effluent was 
introduced onto a triple quadrupole mass spectrometer 6410 
(Agilent Technologies, Palo Alto, CA, USA) and analysed using 
electrospray ionisation in the positive ion mode with multiple 
reaction monitoring. Data was acquired using MassHunter 
acquisition software (Agilent Technologies revision B.04.00, 
Palo Alto, CA, USA).
Statistical analysis
A Kruskal–Wallis rank test with a post hoc test was used to cal-
culate multiple comparisons of the studied groups of patients. 
The statistical relations between two variables were found 
using Spearman’s rank coefficient. The results were considered 
statistically significant when p < 0.05. All calculations were 
performed using STATISTICA v.13.1 (StatSoft. Inc., USA).
Results
The levels of Cer-C14:0, Cer-C24:0, Cer-C20:0 and Sph-1-P 
are augmented, and Cer-C24:1 decreased, in serum of patients 
with acute ischaemic stroke.
Multiple significant changes in SF plasma concentrations were 
found in patients with acute ischaemic stroke compared to 
non-stroke participants.
The acute stroke-induced changes in levels of several Cer 
species are shown in Figs. 1A, B. Significantly augmented 
concentrations of Cer-C14:0 (p = 0.049) and Cer-C24:0 
(p = 0.023) were found in patients after acute stroke when 
compared to the group of patients without stroke. Particularly 
high increments were noted for Cer-C20:0 (p < 0.001), the 
content of which was almost doubled in people with brain 
infarction (Fig. 1A). In contrast, the levels of Cer-C24:1 
(p = 0.013) were significantly decreased in subjects with acute 
stoke. Cer-C24:1 was the only studied SF of which the concen-
trations were lower in the stroke population than in the group 
without stroke (Fig. 1B). Moreover, the levels of Cer-C24:1 
showed a significant inverse correlation with the time after 
stroke onset (R = –0.40, p = 0.012), but not with any other 
analysed parameters (Fig. 1C). This suggests that Cer-C24:1 
is an independent parameter related to the course of stroke. 
The concentrations of Cer-C16:0 (not shown) and Cer-C18:0 
(Fig. 1C) positively correlated with NIHSS (R = 0.46, p = 0.003; 
R = 0.39, p = 0.011, respectively), although their levels were 
not significantly altered in acute stroke. 
On the other hand, both SF species showed positive rela-
tions with the presence of diabetes (Cer-C16:0 — R = 0.38, 
p = 0.014; Cer-C18:0 — R = 0.46, p = 0.003) (Cer-C16:0 
— not shown; Cer-C18:0 — Fig. 1C), but diabetes by itself was 
a  predictive factor for poor patient outcomes after stroke 
(R = 0.53, p < 0.001). An acute stroke led also to a significant 
elevation of Sph-1-P in blood serum (p = 0.020) (Fig.1A), 
although levels of Sph-1-P did not correlate either with time 
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Figure 1. Levels of individual Cer species and Sph-1-P in blood serum (A, B) and their selected correlations with the number of days after 
ischaemic stroke onset, NIHSS, and diabetes (C). The concentrations of studied SF species are presented as median (Q1–Q3) values. Se-
lected Spearman’s rank correlations are shown as scatter graphs (number of days after ischaemic stroke onset and NIHSS). Correlations 
between levels of selected SFs and diabetes are presented on plots of SF concentration median (Q1–Q3) values in ischaemic patients with 
and without diabetes
*p < 0.05
***p < 0.001 versus controls 
TIA — transient ischaemic attack; IS — ischaemic stroke
after stroke onset or with NIHSS. The serum concentrations of 
those SFs which were altered in acute ischaemic stroke were 
also slightly changed in TIA patients, although not sufficiently 
to reach statistical significance.
All Spearman’s rank correlation coefficients, calculated be-
tween levels of individual Cer species as well as Sph-1-P and 
number of days after stroke, and NIHSS, are set out in Table 
2. Selected scatter graphs are shown in Figure 1C.
The serum ratios of Sph-1-P / C24:1 and C24:0 / Cer-C24:1 
are strongly increased in patients with acute ischaemic stroke, 
and Sph-1-P / C24:1 ratios are raised after TIA.
To strengthen the accuracy of the SF system in potential stroke 
diagnostics, we calculated ratios:
1) Sph-1-P / individual Cer species and 2) individual Cer spe-
cies / Cer-C24:1. The first ratio was chosen so as to integrate 
factors reflecting clot formation (Sph-1-P) and BBB damage 
(Cer). The second ratio was evaluated having regards to the 
fact that Cer-C24:1 was the only studied Cer species exhibiting 
a significant decrease in stroke patients. Most studied ratios of 
Sph-1-P / individual Cer species were significantly changed 
in patients with acute stoke compared to non-stroke controls, 
although most of the alterations were quite modest. Among 
calculated Sph-1-P / Cer ratios, Sph-1-P / Cer-C24:1 was 
found to be highly augmented in patients with acute stroke 
(p < 0.001) (Fig. 2). Moreover, Sph-1-P / Cer-C24:1 was also 
significantly increased in people after TIA compared to non-
-ischaemic controls (p = 0.008) (Fig. 2).
Similarly, most of the studied ratios of individual Cer spe-
cies / Cer-C24:1 were significantly higher in patients who 
had experienced an acute ischaemic stroke compared to the 
non-stroke group, but especially high values were found for 
Cer-C24:0 / Cer-C24:1 (p < 0.001) (Fig. 2). Interestingly, cho-
osing a value of Q3 of control as a reference, we found that 
over 80% of patients with acute stroke, and 60% of patients 
after TIA, presented Sph-1-P / Cer-C24:1 values above Q3 of 
control (Fig. 2). Similarly, approximately 80% of stroke patients 
showed Cer-C24:0 / Cer-C24:1 ratios higher than value of Q3 
of control (Fig. 2).
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Figure 2. Selected ratios of blood serum SFs. Values of SF ratios 
are presented as median (Q1–Q3) values. Percentage of patients 
presented selected SF ratio values in relation to Q3 of control as 
a reference is shown as % of cases above and below Q3 of control 
**p < 0.01, ***p < 0.001 versus control
 TIA — transient ischaemic attack; IS — ischaemic stroke
The correlations between levels of Cer, Sph-1-P as well as 
chosen SF ratios and selected clinical parameters in patients 
with acute ischaemic stroke.
Several clinical conditions, such as diabetes, hypercholestero-
lemia and hypertriglyceridemia as well as renal disease, which 
presented in subpopulations of patients with acute ischaemic 
stroke, were analysed in order to assess their potential corre-
lations with studied SFs and chosen SF ratios (Tab. 2). No sig-
nificant correlations between studied SFs or selected SF ratios 
and hypercholesterolemia or renal disease were found in people 
after acute stroke. In turn, the presence of hypertriglyceridemia 
exhibited weak positive correlations only with Cer-C18:0 con-
centrations and Cer-C18:0 / Cer-C24:1 ratios in stroke patients. 
Furthermore, levels of Cer-C16:0 and Cer-C18:0, as well as their 
ratios: Cer-C16:0 / Cer-C24:1, Cer-C18:0 / Cer-C24:1, Sph-1-
-P / Cer-C16:0, Sph-1-P / Cer-C18:0 significantly correlated 
with the presence of diabetes in stroke patients. In addition, 
the overall group of participants (n = 97–99), including people 
with acute stroke, TIA and non-stroke controls was analysed 
in order to find the potential correlations of studied SFs with 
age and sex (not shown). Among the studied parameters, only 
concentrations of Cer-C14:0 showed faint correlations with age. 
No other statistically significant correlations with age and sex 
were reported, which excludes the possibility that the observed 
changes in SF levels were related to ageing or may have been 
influenced by the sex of the patient.
Discussion
Despite the SF system having been tested for potential diagno-
stic utility in several diseases [21–23], the only study showing 
dramatic changes of numerous Cer species in CSF in stroke was 
focused on subarachnoid haemorrhages [24]. No conclusive 
research has been performed in ischaemic stroke, even though 
Cer is considered to be an important factor contributing to 
atherosclerotic plaque formation [25]. Recently, Laaksonen et 
al. (2016) [26] proved that several Cer species, and particularly 
their specific ratios, were strong predictors of death risk in 
cardiovascular disease, independent of other lipid markers.
In our study, we found significantly augmented serum content 
of Cer-C14:0, Cer-C24:0 and particularly strong elevation of 
Cer-C20:0 in patients after ischaemic stroke. It should be noted 
that concentrations of all these forms of Cer were increased 
in a heterogeneous group of stroke patients, covering a range 
of more than a week after stroke onset. This suggests that the 
observed changes may be sustained for a longer period of time, 
which makes these Cer species good candidates to be stroke 
biomarkers. Surprisingly, we noted that levels of Cer-24:1, as 
the only Cer species, were significantly diminished in stroke 
patients. Moreover, Cer-C24:1 was the only studied SF, which 
correlated inversely with the number of days after stroke 
onset. Thus, its levels were decreased over time in the course 
of a stroke. The altered Cer species did not correlate with cho-
lesterol levels, which clearly shows that serum concentrations 
of these Cer forms are not elevated as a consequence of higher 
content of their carriers. 
This makes Cer an independent indicator of ischaemic stroke. 
Furthermore, we observed positive correlations of Cer-C18:0 
and Cer-C16:0 with NIHSS, indicating worse outcomes of 
patients with high levels of these Cers. However, we found 
that serum concentrations of both Cers correlated with the 
presence of diabetes, which is associated with a  poor pro-
gnosis for stroke
patients [27]. Therefore, Cer-C18:0 and Cer-C16:0 cannot 
be taken into account as independent prognostic markers in 
ischaemic stroke.
We have shown that, along with Cer, Sph-1-P serum concen-
trations were significantly augmented as a result of cerebral 
infarction. Similarly to Cer, Sph-1-P was found to have ac-
cumulated in ischaemia-insulted brain regions, but as late as 
seven days after stroke onset [28]. On the contrary, early after 
focal cerebral ischaemia, Sph-1-P was depleted from dama-
ged brain tissue. During thrombosis, circulating Sph-1-P is 
massively released from platelets, which increases substantially 
its blood content [17]. Sph-1-P has been shown to promote 
clotting [18], which would be an undesirable effect for patients 
with ischaemic stroke.
Although no significant alterations in studied SFs were found 
in patients after TIA, we observed minor fluctuations of these 
lipids directed similarly to changes of respective species in 
acute stroke. This suggests that TIA also influences Cer and 
Sph-1-P serum profiles, but to a much smaller extent than 
acute ischaemic stroke. Moreover, since TIA does not produce 
an extensive brain insult, TIA-evoked SF alterations are less 
abundant and a short period of time is sufficient to restore 
their blood balance.
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Table 2. Spearman’s rank correlation coefficients between serum levels of individual Cer species, Sph-1-P as well as Sph-1-P / individual Cer species and 
individual Cer species / Cer-C24:1 ratios, and selected patient parameters in the ischaemic stroke group 
Day after admission NIHSS Diabetes HCHOL HTG Renal disease
Cer-C14:0 (ng / ml) -0.04 0.08 -0.03 -0.22 -0.22 0.09
Cer-C16:0 (ng / ml) 0.04 0.46 ** 0.38 * -0.1 0.22 -0.05
Cer-C18:0 (ng / ml) 0.02 0.39 * 0.46** -0.18 0.32* -0.1
Cer-C20:0 (ng / ml) -0.29 -0.04 -0.19 -0.03 -0.03 -0.05
Cer-C24:0 (ng / ml) -0.02 -0.16 -0.02 -0.18 -0.25 -0.12
Cer-C24:1 (ng / ml) -0.40 * 0.14 -0.1 -0.22 -0.15 -0.01
Sph-1-P (ng / ml) -0.25 0.01 0.1 0.13 0.06 -0.08
Cer-C14:0 / Cer-C24:1 0.24 -0.06 0.14 0.02 0.06 0.19
Cer-C16:0 / Cer-C24:1 0.29 0.45** 0.47** 0.06 0.27 -0.14
Cer-C18:0 / Cer-C24:1 0.16 0.33* 0.42** 0.00 0.37* -0.07
Cer-C20:0 / Cer-C24:1 0.18 0.01 -0.07 -0.02 -0.02 -0.02
Cer-C24:0 / Cer-C24:1 0.31 -0.27 0.02 0.00 -0.19 0.14
Sph-1-P / Cer-C14:0 -0.28 -0.04 0.07 0.20 0.10 -0.04
Sph-1-P / Cer-C16:0 -0.25 -0.31* -0.15 0.12 -0.14 0.06
Sph-1-P / Cer-C18:0 -0.18 -0.35* -0.27 0.20 -0.26 0.02
Sph-1-P / Cer-C20:0 -0.07 -0.06 0.17 0.27 0.13 0.14
Sph-1-P / Cer-C24:0 -0.26 0.09 0.20 0.17 0.14 -0.01
Sph-1-P / Cer-C24:1 -0.12 -0.14 0.17 0.20 0.05 0.03
*p < 0.05, ***p < 0.001 versus control 
HCHOL — hypercholesterolemia; HTG — hypertriglyceridemia
In order to strengthen the sensitivity of our measurements, we 
calculated numerous SF ratios, seeking those that were highly 
altered in ischaemic stroke / TIA. We selected two ratios which 
could potentially be applied in stroke diagnostics: Cer-C24:0 
/ Cer-C24:1 was significantly higher in patients with cerebral 
infarction. A second ratio, Sph-1-P / Cer-C24:1, was highly 
augmented not only in stroke patients, but also in people who 
had experienced TIA, which suggests its potential utility in TIA 
diagnostics. It should be noted that increments in the above-
mentioned SF ratios in stroke patients had greater statistical 
power than the changes in levels of individual SF species. Thus, 
we suggest that in further studies toward elaborating SF-based 
diagnostic tests, the use of SF ratios is highly desirable.
An important issue in studies on humans is the selection 
of control groups. In our study, the control group consisted 
of patients with various neurological disorders, but not 
ischaemic stroke / TIA. The control group matched the age 
and sex distributions of the stroke and TIA groups, as well 
as involving participants with similar comorbid diseases to 
ischemic patients. In that way, we could verify whether it is 
possible to distinguish patients with brain ischaemia from 
those with other causes of neurological dysfunction by using 
SF measurements.
The question arises as to what is the source of the increments 
in serum Cer levels? One possibility is associated with a reca-
nalisation event. Full recanalisation is highly desirable within 
the first hours after a stroke [29]. However, unblocking an 
occluded vessel in the later stages of an ischaemic stroke can 
cause paradoxical effects such as a deterioration in the patient’s 
condition [30]. Inflammatory processes in the infarcted brain 
areas lead to BBB damage [31], and subsequent reopening of 
the vessel results in a massive influx of immune cells into the 
brain parenchyma. On the other hand, it also allows for the 
leakage of factors produced in affected brain regions to the 
circulation. However, such events can be temporarily limited 
to the sub-recanalisation period. Thus, some Cer species 
accumulated in the brain in the early stages of stroke may 
be released to the blood rapidly during reperfusion, and stay 
invisible in analysis encompassing a range of up to 20 days 
after stroke onset.
It has been reported that Cer in an ischaemic brain is gene-
rated both due to de novo synthesis as well as sphingomyelin 
hydrolysis [6–8, 32]. Although these observations seem incon-
sistent at first glance, they are not necessarily contradictory. 
Cer can be generated in the ischaemic brain over a  longer 
time, first being produced early after stroke onset through SM 
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hydrolysis, and then several days after the stroke incident in 
de novo synthesis pathway. Thus, accumulations of different 
Cer species in the insulted cerebral areas may be observed at 
different stroke stages. In blood, Cer has been shown to be 
a  stimulator of tissue factor (TF) activity [33]. Because TF 
is essential in blood coagulation, the increased levels of Cer 
could contribute to the generation of a thromboembolism and 
predispose patients to recurrent strokes, which would be an 
additional aspect of Cer action.
It worth mentioning that the medications of patients used for 
the treatment of ischaemic stroke can influence the profile of 
plasma sphingolipids. Similarly, exposure to statins due to 
common chronic conditions affects plasma levels of a wide 
spectrum of lipids and sphingolipids [34]. Both factors should 
be considered in further studies performed on a larger cohort 
of patients.
Conclusions
We found serum SFs to be good candidates to be ischaemic stro-
ke biomarkers. We identified two SF ratios, Sph-1-P / Cer-C24:1 
and Cer-C24:0 / Cer-C24:1, with strong diagnostic potential 
in ischaemic stroke. We found Sph-1-P / Cer-C24:1 ratio to 
be possibly useful in TIA diagnostics, also over the long term 
after an ischaemic incident, something which is essential in 
anti-stroke preventive treatment.
Abbreviations: Cer — ceramide; Sph-1-P — sphingosine-1-
-phosphate; TIA — transient ischaemic attack; SF — sphingo-
lipid; CT — computer tomography; IS — ischaemic stroke; MRI 
— magnetic resonance imaging; BBB — blood brain barrier; 
GFAP — glial fibrillary acidic protein; NIHSS — NIH Stroke 
Scale; CSF — cerebrospinal fluid
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